Old drug, new hope for right heart failure?
NCT ID NCT03344159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug spironolactone in 15 adults with chronic right-sided heart failure. The goal was to see if it is safe and can improve heart function and reduce stress on the heart. Participants took either the drug or a placebo to compare effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
15 people
The number who actually took part.
- Started
-
Apr 2018
- Finished
-
May 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Provide a personally signed and dated inform consent form. * Male or female ≥ 18 years. * Able to comply with all study procedures. * History of right heart failure (RHF) secondary to either: i) WHO, group 1 pulmonary arterial hypertension PAH OR ii) WHO group II PH with normal LV systolic function OR iii) WHO group III or IV PH OR iv) primary RV cardiomyopathy. * Current NYHA II-IV * RV dysfunction as measured by 2D echocardiogram: i)defined as a tricuspid annular plane systolic excursion (TAPSE) \<16 mm ii) and /or a two dimensional fractional area change \<35% on screening echo plus * NT-proBNP\>400 pg/ml * Chronic use of diuretics * Clinical stability: defined as no need for increased diuretics, hospitalization or emergency room visit 3 months prior to enrollment Exclusion Criteria: * Patients on chronic MRA therapy or other potassium sparing diuretics. * Baseline serum potassium\>5 ummol/l. * Estimated glomerular filtration rate \<30 ml/min. * LV ejection fraction \<45%, * Moderate or severe LV diastolic function, * Moderate or severe aortic or valvular disease. * Patients requiring augmentation of diuretics or otherwise not meeting definition for clinical stability. * Severe Liver Failure (Child-Pugh Class C) * Claustrophobia or inability lie still in a supine position * Patients with contraindications to either PET or CMR imaging * Pregnancy or lactation. * Unable to provide consent and comply with follow up visits.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiomyopathy right ventricular are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y4W7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- A 10-Question survey could give brazilian pulmonary hypertension patients a voice in their care
- Experimental blood pressure drug put to the test in healthy volunteers
- Can a new drug keep pulmonary arterial hypertension in check over the long haul?
- Could light leg workouts revive Oxygen-Starved muscles in PAH?
- Texting therapy: could a simple phone message boost exercise and quality of life in a rare lung disease?